Clinical Trial Update: Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for CD40L-augmented tumor-infiltrating lymphocytes in EGFR, ALK, ROS1 or HER2-driven non-small cell lung cancer; currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CD40L-Augmented TIL

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | Phase 1 | Status: RECRUITING